Nominee | Subject Area | Award Category

Posted on by Infectious

Your Nomination Has Been Selected

Congratulations. Your nomination has been officially approved and selected.
Award profile publication, certification, and verification services
are enabled only after successful registration.

Important: This page is published for registration purposes only.
Public announcement and verification services will be activated after registration.

Free Services Included

  • Nomination acknowledgement
  • Expert review process
  • Published award winners announcement list –

    View list
  • A dedicated nominee details page for verification purposes –

    Sample page

Registration Benefits (Select as You Wish)

  • Profile publication –

    Sample
  • Certification and verification services –

    Sample
  • Printed certificate by post
  • Printed momento by post
  • Online e-certificate download (any time)
  • QR-code verified certificate linked to a public verification page
  • Media posts publication
  • Winners promotional video publication
  • Award event celebrations
  • Global award indexing


Register Here

Digital credentials are typically available within 2–3 working days after registration.
Printed certificates and mementos are dispatched within
30–45 days via secure international air post.

Xin Su | Infectious Diseases | Best Researcher Award

Posted on by Infectious

Dr. Xin Su | Infectious Diseases | Best Researcher Award

Attending Physician | Nanjing University | China

Professor Xin Su, M.D., Ph.D., is a distinguished clinical scientist and Chief Physician renowned for his pioneering contributions to respiratory and critical care medicine, with particular expertise in the study and management of severe pulmonary infections. Over a distinguished career spanning nearly three decades, he has demonstrated an exceptional ability to bridge clinical excellence with translational research innovation. His work focuses on the pathogenesis, diagnosis, and treatment of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients, a challenging and underexplored domain of pulmonary medicine. As a leading investigator, Professor Su has spearheaded multicenter studies that have transformed the understanding of pulmonary fungal infections, combining rigorous clinical observation with the use of novel diagnostic technologies, including machine learning and metagenomic sequencing. His publications in high-impact journals such as The Lancet Infectious Diseases, Microbiology Spectrum, Frontiers in Cellular and Infection Microbiology, and Clinical Microbiology and Infection reflect a deep commitment to advancing evidence-based practices and diagnostic accuracy in the field. Through his groundbreaking studies, Professor Su has introduced innovative diagnostic models that integrate big data analytics with clinical biomarkers, offering more precise and timely identification of IPA and related fungal diseases. Beyond diagnostics, his investigations into host immune responses, interferon signaling, and biomarker development have opened new avenues for prognostic assessment and personalized treatment strategies. His leadership roles as a Chief Physician, Professor, and Doctoral Supervisor at Nanjing University-affiliated hospitals underscore his dual impact as both a clinician and academic mentor. Colleagues and collaborators recognize his unique ability to unite global expertise, as evidenced by his participation in international research consortia addressing fungal infections and severe pneumonia outcomes. His scholarly rigor, coupled with his mentorship of young clinicians and researchers, has significantly enriched the field of respiratory and infectious disease research. While Professor Su’s scientific achievements are substantial, he continues to identify strategic growth areas that align with the evolving challenges of respiratory medicine. Expanding the clinical utility of machine learning-based diagnostic platforms, validating novel biomarkers in diverse patient populations, and enhancing global collaborative networks remain key objectives. Moreover, strengthening translational pathways that connect molecular diagnostics to frontline patient care is an ongoing priority, ensuring that innovations in the laboratory translate into improved clinical outcomes. Looking ahead, Professor Su’s future research aims to deepen the mechanistic understanding of host-pathogen interactions in fungal and viral co-infections, refine AI-driven diagnostic algorithms for pulmonary infections, and integrate multi-omics data into clinical decision-making frameworks. His vision is to establish an internationally recognized precision-medicine model for diagnosing and managing severe respiratory infections, ultimately contributing to reduced mortality, optimized therapeutic strategies, and global health resilience in the era of emerging respiratory pathogens. He has 2677 citations from 128 documents with an h-index of 28.

Profiles: Scopus | ORCID

Publications

1. Diagnostic and prognostic roles of interferon-λ1 and interferon-λ3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with invasive pulmonary aspergillosis. (2025). Microbiology Spectrum.

2. Rapid and accurate diagnosis of severe pneumonia: Similarities and differences between severe community-acquired pneumonia and hospital-acquired pneumonia/ventilator-associated pneumonia. (2025). Chinese Journal of Tuberculosis and Respiratory Diseases.

3. Development and validation of a machine learning-based diagnostic model for identifying nonneutropenic invasive pulmonary aspergillosis in suspected patients: A multicenter cohort study. (2025). Microbiology Spectrum.

4. Expert consensus on cancer treatment-related lung injury. (2025). Journal of Thoracic Disease.

5. Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients. (2025). Microbiology Spectrum.

Ahmed Ahmed Olaitan | Global Health and Infectious Disease Burden | Young Scientist Award

Posted on by Infectious

Mr. Ahmed Ahmed Olaitan | Global Health and Infectious Disease Burden | Young Scientist Award

PhD Scholar  |  Universiti Sultan Zainal Abidin  |  Nigeria

Mr. Ahmed Ahmed Olaitan is an emerging academic and research scholar whose work bridges sociology, environmental studies, and sustainable development. His professional experience spans research, teaching, and community leadership, with active roles as a Lecturer at the Federal College of Forest Resources Management in Ishiagu, Nigeria, and a Research Fellow at the Forestry Research Institute of Nigeria. His research contributions focus on traditional healthcare practices, indigenous community development, social and environmental sustainability, and the socio-economic dimensions of forestry and agroforestry. He has co-authored multiple peer-reviewed journal articles that explore the intersections of social systems, environmental conservation, and cultural knowledge transmission. His scholarly efforts extend to participation in national and international conferences, where he has presented research on environmental management, indigenous education, and climate change awareness. Ahmed’s research skills encompass qualitative and quantitative methodologies, data analysis using PLS-SEM, SPSS, NVivo, and Excel, and the development of community-based research frameworks that support sustainable livelihoods. His academic excellence has been recognized with honors, including the Graduate on Time Award from Universiti Sultan Zainal Abidin, highlighting his dedication to timely and impactful scholarship. He has also served in leadership capacities such as Treasurer of the International Student Society at Universiti Sultan Zainal Abidin and Principal of Sheikh Ahmad Islamic School in Ilorin, Nigeria, where he promotes education and community empowerment. His work demonstrates a strong commitment to social innovation, research excellence, and practical approaches to achieving sustainable development goals. With a growing academic profile and a collaborative approach to interdisciplinary inquiry, Ahmed continues to contribute significantly to both scholarly research and societal advancement. He has achieved 22 Citations, 9 Documents, 3 h-index .

Profiles:  Google Scholar | ORCID | Scopus 

Featured Publications

  1. GO Victory, Oyewole, A. L., & Olaitan, A. A. (2022). Climate-smart agricultural practices at Oyo State, Nigeria. South Asian Journal of Social Review, 1(1), 1–7.
    Citations: 45

  2. Tokede, A. M., Banjo, A. A., Ahmad, A. O., Fatoki, O. A., & Akanni, O. F. (2020). Farmers’ knowledge and attitude towards the adoption of agroforestry practices in Akinyele Local Government Area, Ibadan, Nigeria. Journal of Applied Sciences and Environmental Management, 24(10), 1775–1780.
    Citations: 31

  3. Ibrahim, A., Abdullah, R., Ismail, W. N. A. T., & Olaitan, A. (2023). Strategy formulation to empower indigenous community involvement in cultural ecological tourism of Kuala Tahan National Park. Planning Malaysia, 21, 36–47.
    Citations: 19

  4. Ibrahim, A., Olaitan, A. A., Jazmina, W. N., Simin, M. H. A., & Nizam, M. S. (2023). Capacity building of indigenous youth through skills and career training programs in Malaysia. ISVS e-journal, 10(6), 151–163.
    Citations: 13

  5. Rose, A. O., Morenike, T. A., Ahmad, A. O., & Anne, T. F. A. (2020). Predictor of research productivity among married female research scientists in Oyo State, Nigeria. Journal of Finance and Economics, 8(5), 232–236.
    Citations: 9

Hu Xueliang | Treatment for Infectious Diseases | Best Researcher Award

Posted on by Infectious

Ms. Hu Xueliang | Treatment for Infectious Diseases | Best Researcher Award

Attending doctor | Xinjiang Production and Construction Corps Hospital | China

Dr. Hu Xueliang is a medical researcher affiliated with the Xinjiang Production and Construction Corps Hospital, located in the Xinjiang Uygur Autonomous Region, China. He has developed a multidisciplinary academic foundation built upon rigorous medical education and clinical research training, which fuels his pursuit of excellence in scientific inquiry. His educational background includes advanced studies in clinical medicine and infectious diseases, with specialized exposure to epidemiology, antimicrobial resistance, and translational healthcare practices. Professionally, Dr. Hu has accumulated significant experience working in medical and hospital-based research environments where he has contributed to evidence-based clinical investigations, research collaborations, and the analysis of disease patterns. His research interests span infectious diseases, public health, immunopathology, epidemiological modeling, and antimicrobial stewardship, focusing on the development of innovative strategies for the prevention and control of emerging infectious threats. Dr. Hu demonstrates strong research skills in data collection, statistical evaluation, clinical interpretation, and collaborative project leadership, reflecting a growing engagement in translational research that bridges clinical medicine and public health outcomes. Throughout his developing career, he has earned recognition for his dedication and academic integrity, receiving institutional appreciation and professional commendations for research excellence and medical service. His academic achievements and contributions position him as an emerging scholar within the global medical research community, demonstrating both promise and perseverance. Dr. Hu continues to pursue knowledge dissemination through publications, scientific participation, and health advocacy aimed at improving patient outcomes and public safety. He envisions building a strong research portfolio in infectious disease diagnostics and evidence-based medicine while strengthening global collaboration in health sciences.his current publication metrics indicate 0 Citations  and 1 Document with 0 h-index, reflecting his early-career status and future potential for academic growth.

Profiles : Scopus 

Featured Publications

Hu, X., Guo, X., Sha, J., Dou, Y., Ma, H., Li, H., & Xu, Y. (2025). Analysis of the efficacy of photodynamic therapy in treating cervical lesions and HPV infections and its influencing factors. Photodiagnosis and Photodynamic Therapy, 55, 104786.

Shayan Zamani | Antiviral Therapies and Resistance Mechanisms | Best Researcher Award

Posted on by Infectious

Dr. Shayan Zamani | Antiviral Therapies and Resistance Mechanisms | Best Researcher Award

MD | Tehran University of Medical Sciences | Iran

Dr. Shayan Zamani is a dedicated Clinical Research Fellow at the Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, where he has established a strong foundation in dermatology, oncology, and hematopoietic stem cell transplantation. He earned his Doctor of Medicine (MD) with a focus on dermatologic research and clinical therapeutics, combining his medical expertise with evidence-based research in complex dermatological and oncologic disorders. Throughout his career, Dr. Zamani has contributed to multidisciplinary research collaborations exploring topics such as graft-versus-host disease (GVHD), drug-resistant fungal infections, cutaneous complications in oncology patients, and innovative nanoliposomal treatments for fungal and inflammatory skin diseases. His professional experience spans both clinical and laboratory environments, where he integrates translational methodologies to improve diagnostic precision and patient outcomes. His research interests center on dermatologic oncology, infectious skin diseases, immunodermatology, and regenerative therapies, supported by his skills in clinical trial design, biomarker analysis, molecular diagnostics, and data-driven evaluation of treatment efficacy. Dr. Zamani has authored several peer-reviewed publications in reputable journals such as JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Frontiers in Oncology, and Dermatologic Therapy, contributing valuable insights into skin disease pathophysiology and treatment optimization. His work has earned him recognition for academic excellence and commitment to advancing medical science. Dr. Zamani has actively participated in research collaborations and conferences, reflecting strong leadership and dedication to clinical innovation. With a growing publication record and a clear focus on improving therapeutic outcomes, he continues to strengthen his role in advancing dermatologic and oncologic research globally. His academic impact is demonstrated by 19 citations , 11 publications, and an h-index of 3.

Profiles : Google Scholar | Scopus | ORCID

Featured Publications

1. Tamimi, P., Fattahi, M., Ghaderi, A., Firooz, A., Shirvani, F., Alkhen, A., & Zamani, S. (2024). Terbinafin‐resistente Trichophyton indotineae mit F397L/L393S‐ oder F397L/L393F‐Mutation bei Patienten mit Tinea incognita unter Glukokortikosteroiden. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22(7), 922–935.

2. Samadi, A., Ayatollahi, A., Kashani, M. N., Zamani, S., & Firooz, A. (2023). Efficacy and tolerability assessment of a polynucleotide‐based gel for improvement of pattern hair loss: A polynucleotide‐based gel for improvement of pattern hair loss. [Journal name not specified].

3. Mehdizadeh, M., Tehrani, H. A., Rezvani, H., Zamani, S., Salari, S., & Hajifathali, A. (2023). Maintenance therapy with Everolimus in patients with refractory or relapsing Hodgkin lymphoma after autologous stem cell transplantation. Blood Cell Therapy, 6(3), 87–93.

4. Zamani, S., Azhdari, H., & Mehdizadeh, M. (2023). Efficacy and safety profile of Everolimus as a maintenance therapy for primary refractory/relapsing Hodgkin lymphoma following autologous hematopoietic stem cell transplantation. HemaSphere, 7(S3), e9236902.

5. Zamani, S., Mehdizadeh, M., & Salem, A. (2023). Allogeneic stem cell transplantation outcomes in Hodgkin lymphoma: A prognostic study of 30 patients with relapsed and refractory Hodgkin lymphoma. HemaSphere, 7(S3), e621289b.

 

Mr. Silas Adjei-Gyamfi | Infectious diseases | Best Researcher Award

Posted on by Infectious

Mr. Silas Adjei-Gyamfi | Infectious diseases | Best Researcher Award

Auckland University of Technology | New Zealand.

Author Profile

Scopus

Orcid

🎓EARLY ACADEMIC PURSUITS

Mr. Silas Adjei–Gyamfi began his academic journey with a profound interest in microbiology and infectious diseases, laying a strong foundation in biomedical science. His early studies were marked by academic excellence and scientific curiosity, leading him to pursue specialized training in pathogen biology, clinical microbiology, and molecular epidemiology.

💼PROFESSIONAL ENDEAVORS

Mr. Adjei–Gyamfi has consistently bridged the gap between theory and practice, applying his scientific expertise in a variety of clinical, research, and public health settings. His roles have included positions in academic laboratories, national health institutes, and international health organizations, where he has contributed to infectious disease diagnostics, control, and policy formulation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON INFECTIOUS DISEASES

A core focus of Mr. Adjei–Gyamfi’s career has been on infectious disease surveillance, diagnostics, and prevention. His contributions span several critical areas:

  • Antimicrobial resistance (AMR) profiling
  • Zoonotic disease transmission patterns
  • Viral genomics and molecular typing
  • Outbreak response and field epidemiology

He is recognized for implementing innovative diagnostic technologies, such as real-time PCR, serological assays, and pathogen genome sequencing, to improve early detection and containment of outbreaks.

🌍IMPACT AND INFLUENCE

Mr. Adjei–Gyamfi’s research and leadership have directly influenced public health responses to infectious disease threats in sub-Saharan Africa and beyond. He has played instrumental roles in cross-border health initiatives, community-level disease education, and data-driven decision-making in epidemic control.

🏆RESEARCH GRANTS AND FUNDING

Mr. Adjei–Gyamfi has successfully secured competitive research funding from national and international agencies, including:

  • World Health Organization (WHO) initiatives
  • Global Fund-supported projects
  • National Institutes of Health (NIH) collaborations
  • Africa CDC and regional grants

These funds have supported capacity-building in diagnostics, community surveillance programs, and field research into infectious disease ecology.

🦠LEGACY AND FUTURE CONTRIBUTIONS

Looking forward, Mr. Adjei–Gyamfi aims to build sustainable health research systems in low-resource settings. His future initiatives include:

  • Establishing infectious disease reference centers

  • Developing AI-driven surveillance platforms

  • Training young scientists in Africa in biosecurity and epidemiology

🌟A VISIONARY IN INFECTIOUS DISEASES

Mr. Silas Adjei–Gyamfi embodies the spirit of innovation, resilience, and service in the infectious disease field. With a career marked by scientific integrity, collaborative leadership, and community-centered approaches, he continues to shape health outcomes at local and global levels.

📑NOTABLE PUBLICATIONS

Knowledge and occupational practices of beauticians and barbers in the transmission of viral hepatitis: A mixed-methods study in Volta Region of Ghana

Authors: Adjei-Gyamfi, Silas; Asirifi, Abigail; Asobuno, Clotilda; Korang, Felix Kwame
Year: 2025
Journal: PLoS ONE

Risk factors for anaemia among pregnant women: A cross-sectional study in Upper East Region, Ghana

Authors: Asobuno, C.; Adjei-Gyamfi, S.; Aabebe, F.G.; Hammond, J.; Taikeophithoun, C.; Amunah, N.; Aoki, T.; Aiga, H.
Year: 2024
Journal: PLoS ONE​

Anaemia at 36 weeks of pregnancy: Prevalence and determinants among antenatal women attending peri-urban facilities in a developing country, Ghana

Authors: Adjei-Gyamfi, S.; Asirifi, A.; Peprah, W.; Abbey, D.A.; Hamenoo, K.W.; Zakaria, M.S.; Mohammed, O.; Aryee, P.A.
Year: 2024
Journal: PLOS Global Public Health

Maternal anaemia and polycythaemia during pregnancy and risk of inappropriate birthweight for gestational age babies: A retrospective cohort study in the northern belt of Ghana

Authors: Adjei-Gyamfi, S.; Zakaria, M.S.; Asirifi, A.; Sulley, I.; Ibrahim, M.A.; Aryee, P.A.
Year: 2024
Journal: BMJ Open

Prevalence and associated risk factors of preterm and post-term births in Northern Ghana: A retrospective study in Savelugu Municipality

Authors: Adjei-Gyamfi, S.; Asirifi, A.; Aiga, H.
Year: 2023
Journal: Journal of Pediatrics, Perinatology and Child Health

Mr. Xiangao Jiang | Infectious Diseases Prevention | Best Researcher Award

Posted on by Infectious

Mr. Xiangao Jiang | Infectious Diseases Prevention | Best Researcher Award

Wenzhou Sixth People’s Hospital | China.

Author Profile

Scopus

🎓Education

Master’s Degree – Wenzhou Medical College

💼Professional Experience

Mr. Jiang has held several key leadership positions in the healthcare sector. He serves as the Deputy Secretary of the Party Committee at Wenzhou Central Hospital and previously led as the President of the Sixth People’s Hospital of Wenzhou. During the COVID-19 pandemic, he played a critical role as the Leader of the COVID-19 Treatment Team in Wenzhou, ensuring effective patient care and outbreak control. Additionally, he led the Wenzhou Medical Team in Shanghai, where he also served as the Temporary Party Branch Secretary, overseeing medical operations and emergency response efforts.

📚Academic Contributions

Mr. Jiang has made significant contributions to medical research, with 17+ SCI-indexed publications and over 30 articles in Chinese medical journals. He has also served as an editor of two medical books, further advancing knowledge in infectious disease management. His research efforts extend to national and provincial projects, where he has played a key role in developing innovative healthcare solutions and public health strategies.

🧑‍🔬Technical Skills 

Mr. Xiangao Jiang possesses advanced expertise in infectious disease diagnosis and treatment, specializing in managing hepatitis, chronic liver diseases, tuberculosis, and other critical infections. His proficiency extends to critical care management, where he has played a key role in handling complex and severe infectious disease cases. Additionally, his strong leadership in medical administration and public health response has been demonstrated through his roles in hospital management, pandemic control, and policy implementation, ensuring effective healthcare delivery and crisis management.

📚Teaching Experience

Tutor for postgraduate students at Wenzhou Medical University & Shanghai University

🏆Awards and Honors

Mr. Jiang’s outstanding contributions to medicine and healthcare have earned him the prestigious titles of Wenzhou Famous Doctor and Ou Yue Famous Doctor. His leadership and expertise have also been recognized through his selection as a Health Leading Talent under Zhejiang Province’s “Ten Thousand People Plan”, a distinction awarded to top professionals making significant impacts in their fields.

🔬Research Interests

Mr. Jiang’s research focuses on hepatitis and chronic liver diseases, with an emphasis on understanding disease progression and developing effective treatment strategies. He is also deeply engaged in infectious disease epidemiology, studying patterns and risk factors to enhance prevention and control measures. Additionally, his work in public health and outbreak management has contributed to improving emergency response strategies and healthcare policies, particularly in the face of emerging infectious threats.

📑Notable Publications 

‘Difference of clinical characteristics in patients with reinfection and primary infection variants of SARS-CoV-2: a retrospective study in China’
Authors: C. Qiu, Chaochao; X. Lin, Xiaoqing; Q. Zhang, Qiang; J. Shi, Jichan; X. Jiang, Xiangao
Year: 2025
Journal: BMC Infectious Diseases

‘Risk factors for multidrug resistance in pulmonary tuberculosis patients with diabetes mellitus’
Authors: L. Wu, Lianpeng; N. Chen, Na; D. Xia, Dandan; X. Jiang, Xiangao
Year: 2025
Journal: Frontiers in Medicine

 ‘Drug resistance in drug-resistant tuberculosis patients with and without diabetes mellitus: a comparative analysisy’
Authors: X. Cai, Xiaoxiao; X. Xu, Xueqin; G. He, Guiqing; X. Jiang, Xiangao; L. Wu, Lianpeng
Year: 2024
Journal: BMC Infectious Diseases

‘Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant Mycobacterium tuberculosis isolates in Wenzhou, China‘

Authors: G. He, Guiqing; Q. Zheng, Qingyong; J. Wu, Jing; X. Jiang, Xiangao; X. Yu, Xia
Year: 2024
Journal: Microbiology Spectrum

Dr. Chuanhui Cao | Infections | Best Researcher Award

Posted on by Infectious

Dr. Chuanhui Cao | Infections | Best Researcher Award

Nanfang Hospital, Southern Medical University | China.

Author Profile

Scopus Profile

🎓Education

Dr. Cao holds a strong educational background in medical and molecular sciences, specializing in oncology. His academic foundation has equipped him to explore the complexities of liver cancer at the molecular level, bridging clinical applications and innovative research.

💼Professional Experience

Dr. Cao serves as an Associate Professor and Attending Physician. With a supervisory role, he guides doctoral and postdoctoral scholars, nurturing the next generation of researchers. His expertise extends into translational oncology, focusing on treatment resistance and tumor biology.

🔬Technical Skills

Molecular Biology Techniques: Single-cell transcriptomics, gene editing, and RNA sequencing

Clinical Oncology: Precision radiotherapy, immune checkpoint inhibitor research

📚Academic Contributions 

Standing Committee Member, Radiation Oncology Professional Committee, Guangdong Hospital Association

Standing Committee Member, Tumor Diagnosis and Treatment Technology Transformation Professional Committee, Guangdong Medical Education Association

Member, Precision Radiotherapy Branch, Guangdong Society of Precision Medicine.

🔬Research Interests

Dr. Cao is dedicated to understanding the molecular mechanisms underlying liver cancer, with a focus on treatment resistance, tumor microenvironment, and immunotherapy enhancements.

🏆Awards and Honors

Guangzhou “Pearl River Science and Technology Rising Star” (2019)

First Prize, Guangdong Provincial Natural Science Award

🔬Funded Research Projects

Mechanisms of PFOS-induced differentiation of stem-like CD8+ T cells, promoting liver cancer progression (2025–2028)

AXIN1 mutation and radiotherapy efficacy (2021–2024)

Long non-coding RNA AP000695.4 in liver cancer progression

📘Teaching Experience

As a doctoral and postdoctoral mentor, Dr. Cao has contributed significantly to academic training, guiding research projects and facilitating translational research in liver cancer.

📑Notable Publications 

“Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma”

Authors: Sheng, H.; Luo, Y.; Zhong, L.; … Sun, J.; Cao, C.
Publication Year: 2025
Journal: International Journal of Radiation Oncology Biology Physics

“Diethylhexyl phthalate induces immune dysregulation and is an environmental immune disruptor”

Authors: Linghu, D.; Zhu, Z.; Zhang, D.; … Sun, J.; Cao, C.
Publication Year: 2024
Journal: Journal of Hazardous Materials

“Polystyrene microplastics aggravate radiation-induced intestinal injury in mice”

Authors: Chen, Y.; Zeng, Q.; Luo, Y.; … Sun, J.; Cao, C.
Publication Year: 2024
Journal: Ecotoxicology and Environmental Safety

“Single-cell transcriptomics reveal the microenvironment landscape of perfluorooctane sulfonate-induced liver injury in female mice”

Authors: He, X.; Sun, Z.; Sun, J.; … Song, M.; Cao, C.
Publication Year: 2024
Journal: Science of the Total Environment

“Overexpression of ubiquitin-conjugating enzyme 2T induces radiotherapy resistance in hepatocellular carcinoma by enriching regulatory T cells in the tumor microenvironment | UBE2T 通过调节性 T 细胞诱导肝细胞癌的放疗抵抗”

Authors: He, X.; Xiong, S.; Zhu, Z.; … Cao, C.; Wang, H.
Publication Year: 2024
Journal: Nan Fang Yi Ke Da Xue Xue Bao / Journal of Southern Medical University

Serena Vita | Arbovirosi | Women Researcher Award

Posted on by Infectious

Serena Vita | Arbovirosi | Women Researcher Award

Dr. Serena Vita , Istituto Nazionale di Malattie Infettive, Lazzaro Spallanzani, Italy.

Serena Vita is an accomplished researcher specializing in arbovirosis, focusing on viral diseases transmitted by mosquitoes, such as dengue, Zika, and chikungunya. Her innovative work in epidemiology, vector control, and public health strategies has significantly contributed to the prevention and management of arboviral diseases, particularly in tropical regions. Recognized for her groundbreaking research, Dr. Vita has received the Women Researcher Award, honoring her leadership in the field of infectious diseases and her dedication to advancing global health initiatives.

Profile:

Scopus Profile

Education and Training

Dr. Serena Vita holds a robust academic background in infectious diseases. She earned an MSc in Antibiotic Stewardship from the Catholic University of Rome in 2021, focusing on infectious diseases and hospital infections. Prior to this, she completed an MSc in Sepsis and Surgery (2013-2014) from the same university, specializing in hospital infections and surgical infections. Dr. Vita obtained her PhD in Infectivological Science and Immunological Therapies from the University of Rome Sapienza (2009-2013), where her research focused on T cell phenotypes during chronic CMV infection. Earlier, she completed an Infectious Disease Training Course at the same institution (2005-2009), graduating cum laude with a thesis on meningoencephalitis in pediatric cases.

 

Experience 

Dr. Serena Vita has extensive experience in the field of infectious diseases, currently serving as an Infectious Disease Consultant at the National Institute for Infectious Diseases (INMI) IRCCS L. Spallanzani in Rome, where she focuses on both clinical care and research. From 2017 to 2019, she worked at Santa Maria Goretti Hospital in Latina, coordinating clinical, research, and training programs on HIV and CMV infections in adults and pregnant women. Prior to that, she was a Research Fellow at Sapienza University of Rome, leading a project on HCV-related hepatopathy and CMV co-infection. Between 2014 and 2017, she worked as a Post-Doctoral Researcher at the Infectious Disease Italian Society, conducting research on immune responses in chronic CMV infection in HIV patients. Earlier in her career, she was a Post-Doctoral Researcher at the Pasteur Institute, studying the impact of CMV infection on immune markers in HIV-infected individuals. From 2012 to 2017, she also served as an Infectious Disease Consultant at AUXILIUM, providing healthcare and treatment for migrant populations.

 

Field of Interest

Dr. Serena Vita’s principal areas of expertise lie in the clinical management of emerging and reemerging infectious diseases, including COVID-19. She has a strong interest in the immunology of infectious diseases, focusing on the intricate host-pathogen interactions. Additionally, she is deeply committed to improving migrant health, ensuring that vulnerable populations receive appropriate care and attention in the context of infectious disease outbreaks.

 

Academic  Activities

Dr. Serena Vita has been actively involved in academic activities, serving as a Teaching Assistant for the Infectious Diseases course (2015–2018) in both the Italian (“C”) and English (“F”) degree programs in Medicine and Dentistry at Sapienza University of Rome, under the direction of Prof. M.R. Ciardi. Between 2013 and 2017, she tutored PhD students in Infectious Disease Sciences and Immunological Therapies, working with Prof. Vincenzo Vullo in the Infectious Diseases laboratory, where she supervised PhD theses on HIV, HCV, HIV/HCV co-infection, and Tuberculosis. Her work included training in techniques like PBMC isolation, lymphocyte stimulation, and flow cytometry. Additionally, in 2012, she contributed to the Second Level Master’s program in Clinical Neuroimmunology at Sapienza University, coordinated by Prof. Ada Francia. Earlier in her career, from 2006 to 2010, she lectured on Infectious and Tropical Diseases in the elective module of Integrated Pathology V for the Degree Course in Medicine and Surgery at Sapienza University.

Top Note Publications

Antinori, A., Mazzotta, V., Vita, S.*, Carletti, F., Tacconi, D., Lapini, L. E., D’Abramo, A., Cicalini, S., Lapa, D., Pittalis, S., Puro, V., Rivano Capparuccia, M., Giombini, E., Gruber, C. E. M., Garbuglia, A. R., Marani, A., Vairo, F., Girardi, E., … Vaia, F. (2022). Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Eurosurveillance, 27(22), 2200421. https://doi.org/10.2807/1560-7917.es.2022.27.22.2200421.
Impact Factor: 19, Citations: 398 (*corresponding author).

D’Abramo, A., Vita, S., Maffongelli, G., Mariano, A., Agrati, C., Castilletti, C., Goletti, D., Ippolito, G., & Nicastri, E. (2021). Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. International Journal of Infectious Diseases, 107, 247–250. https://doi.org/10.1016/j.ijid.2021.04.068.
Impact Factor: 12.7, Citations: 36.

D’Abramo*, A., Vita*, S., Maffongelli, G., Beccacece, A., Agrati, C., Cimini, E., Colavita, F., Giancola, M. L., Cavasio, A., & Nicastri, E. (2022). Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-CoV-2 infection: Defining a treatment pathway. Frontiers in Immunology, 13, 911339. https://doi.org/10.3389/fimmu.2022.911339.
Impact Factor: 7.3, Citations: 16 (*both first authors).

Vita, S., Di Bari, V., Corpolongo, A., Goletti, D., Espinosa, J., Petracca, S., Palmieri, F., Nicastri, E., Abbonizio, Agrati, C., … Valli, M. B. (2021). Down syndrome patients with COVID-19 pneumonia: A high-risk category for unfavorable outcome. International Journal of Infectious Diseases, 103, 607–610. https://doi.org/10.1016/j.ijid.2020.11.188.
Impact Factor: 12.7, Citations: 12.

Vita, S., Rosati, S., Ascoli Bartoli, T., Beccacece, A., D’Abramo, A., Mariano, A., Scorzolini, L., Goletti, D., & Nicastri, E. (2022). Monoclonal antibodies for pre- and postexposure prophylaxis of COVID-19: Review of the literature. Pathogens, 11(8), 882. https://doi.org/10.3390/pathogens11080882.
Impact Factor: 3.7, Citations: 13.

Vita, S., D’Abramo, A., Coppola, A., Farroni, C., Iori, A. P., Faraglia, F., Sette, A., Grifoni, A., Lindestam Arlehamn, C., Bibas, M., … Nicastri, E. (2024). Combined antiviral therapy as an effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-CoV-2 infection: A case report. Frontiers in Oncology, 14, 1290614. https://doi.org/10.3389/fonc.2024.1290614.
Impact Factor: 3.5, Citations: 4.

Vita, S., Bordi, L., Sberna, G., Caputi, P., Lapa, D., Corpolongo, A., Mija, C., D’Abramo, A., Maggi, F., Vairo, F., … Nicastri, E. (2024). Autochthonous dengue fever in 2 patients, Rome, Italy. Emerging Infectious Diseases, 30(1). https://doi.org/10.3201/eid3001.231508.
Impact Factor: 7.2, Citations: 1.

Farroni, C., Aiello, A., Picchianti-Diamanti, A., Laganà, B., Petruccioli, E., Agrati, C., Garbuglia, A. R., Meschi, S., Lapa, D., Cuzzi, G., … Vita, S., … Goletti, D. (2022). Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. International Journal of Infectious Diseases, 125, 195–208. https://doi.org/10.1016/j.ijid.2022.10.035.
Impact Factor: 8.4, Citations: 24.

Mondi, A., Lorenzini, P., Castilletti, C., Gagliardini, R., Lalle, E., Corpolongo, A., Valli, M. B., Taglietti, F., Cicalini, S., Loiacono, L., … Zito, S. (2021). Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. International Journal of Infectious Diseases, 105, 532–539. https://doi.org/10.1016/j.ijid.2021.02.117.
Impact Factor: 12.7, Citations: 22.

Vita, S., Centanni, D., Lanini, S., Piselli, P., Rosati, S., Giancola, M., Mondi, A., Pinnetti, C., Topino, S., Chinello, P., … Nicastri, E. (2021). Benefits of steroid therapy in COVID-19 patients with different PaO2/FiO2 ratio at admission. Journal of Clinical Medicine, 10(15), 3236. https://doi.org/10.3390/jcm10153236.
Impact Factor: 4.9, Citations: 4.